68Ga-PSMA-11 PET 有望优化中高危前列腺癌扩大盆腔淋巴结清扫的患者选择
本研究回顾性分析 60 例接受根治性前列腺切除联合扩大盆腔淋巴结清扫(ePLND)的中高危前列腺癌患者的 68Ga-PSMA-11 PET,评估其预测淋巴结转移的附加价值。视觉分析灵敏度 58%、特异度 98%,原发肿瘤 PSMAtotal 的 ROC 曲线下面积为 0.76。结合 PSA、Gleason 评分、PET 视觉淋巴结状态及原发肿瘤 PSMAtotal 的模型,净获益持续高于五种临床列线图,提示该 PET 有望减少不必要的手术。
要点
- 68Ga-PSMA-11 PET 视觉分析检出淋巴结转移的灵敏度 58%、特异度 98%。
- 原发肿瘤 PSMAtotal 预测淋巴结转移的 ROC 曲线下面积为 0.76,最佳界值 >49.1。
- 结合 PSA、Gleason 评分、PET 视觉淋巴结状态及 PSMAtotal 的模型净获益高于五种临床列线图。
核心结论
- 结合 PSA、Gleason 评分、68Ga-PSMA-11 PET 视觉淋巴结分析及原发肿瘤 PSMAtotal 的模型,在患者选择上较现有临床列线图有改善趋势。
- 68Ga-PSMA-11 PET 显示出减少中高危前列腺癌患者不必要手术的潜力,但结果尚需验证。
研究设计与样本
- 回顾性研究,纳入 60 例接受根治性前列腺切除联合扩大盆腔淋巴结清扫(ePLND)的中高危前列腺癌患者,评估其 68Ga-PSMA-11 PET 扫描。
- 对可疑淋巴结进行定性(视觉)评估,并测量原发肿瘤定量参数 SUVmax、总活性(PSMAtotal)和 PSMA 阳性体积(PSMAvol)。
- 采用受试者工作特征(ROC)分析评估定量 PET 参数预测淋巴结转移的能力,并构建结合 PSA、Gleason 评分、PET 视觉淋巴结状态和原发肿瘤 PSMAtotal 的多变量逻辑回归模型。
- 将各风险阈值下的净获益与五种列线图(MSKCC 列线图、Yale 公式、Roach 公式、Winter 列线图及 Partin 表(2016))进行比较。
主要发现
- ePLND 标本病理共发现 12 例患者存在 31 枚盆腔转移淋巴结。
- 68Ga-PSMA-11 PET 视觉分析在 7 例患者中正确检出可疑淋巴结,灵敏度 58%、特异度 98%。
- 原发肿瘤 SUVmax 的 ROC 曲线下面积为 0.70,PSMAtotal 为 0.76,PSMAvol 为 0.75。
- 淋巴结受累的最佳界值为 PSMAtotal > 49.1。
- 包含 PSA、Gleason 评分和定量 PET 参数的 PET 模型,净获益持续高于所有临床列线图。
关键数值与推荐
- 68Ga-PSMA-11 PET 视觉分析检出淋巴结转移的灵敏度为 58%、特异度为 98%。
- 原发肿瘤 SUVmax 的 ROC 曲线下面积为 0.70,PSMAtotal 为 0.76,PSMAvol 为 0.75。
- 预测淋巴结受累的 PSMAtotal 最佳界值为 >49.1。
临床怎么用
- 对于中高危前列腺癌患者,可考虑应用 68Ga-PSMA-11 PET 视觉淋巴结分析联合原发肿瘤 PSMAtotal 辅助 ePLND 的患者选择。
- 结合 PSA、Gleason 评分、PET 视觉淋巴结状态及 PSMAtotal 的模型净获益高于现有临床列线图,可能帮助减少不必要的 ePLND。
- 上述结果尚需外部验证后方可用于常规临床决策。
局限性
- 本研究为回顾性设计,样本量为 60 例。
- 作者指出结果尚需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Radical prostatectomy with extended pelvic lymph node dissection (ePLND) is a curative treatment option for patients with clinically significant localised prostate cancer. The decision to perform an ePLND can be challenging because the overall incidence of lymph node metastasis is relatively low and ePLND is not free of complications. Using current clinical nomograms to identify patients with nodal involvement, approximately 75-85% of ePLNDs performed are negative. The aim of this study was to assess the added value of 68Ga-PSMA-11 PET in predicting lymph node metastasis in men with intermediate- or high-risk prostate cancer. METHODS: 68Ga-PSMA-11 PET scans of 60 patients undergoing radical prostatectomy with ePLND were reviewed for qualitative (visual) assessment of suspicious nodes and assessment of quantitative parameters of the primary tumour in the prostate (SUVmax, total activity (PSMAtotal) and PSMA positive volume (PSMAvol)). Ability of quantitative PET parameters to predict nodal metastasis was assessed with receiver operating characteristics (ROC) analysis. A multivariable logistic regression model combining PSA, Gleason score, visual nodal status on PET and primary tumour PSMAtotal was built. Net benefit at each risk threshold was compared with five nomograms: MSKCC nomogram, Yale formula, Roach formula, Winter nomogram and Partin tables (2016). RESULTS: Overall, pathology of ePLND specimens revealed 31 pelvic metastatic lymph nodes in 12 patients. 68Ga-PSMA-11 PET visual analysis correctly detected suspicious nodes in 7 patients, yielding a sensitivity of 58% and a specificity of 98%. The area under the ROC curve for primary tumour SUVmax was 0.70, for PSMAtotal 0.76 and for PSMAvol 0.75. The optimal cut-off for nodal involvement was PSMAtotal > 49.1. The PET model including PSA, Gleason score and quantitative PET parameters had a persistently higher net benefit compared with all clinical nomograms. CONCLUSION: Our model combining PSA, Gleason score and visual lymph node analysis on 68Ga-PSMA-11 PET with PSMAtotal of the primary tumour showed a tendency to improve patient selection for ePLND over the currently used clinical nomograms. Although this result has to be validated, 68Ga-PSMA-11 PET showed the potential to reduce unnecessary surgical procedures in patients with intermediate- or high-risk prostate cancer.
引用
- Ferraro DA, Muehlematter UJ, Garcia Schüler HI, et al. 68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31522272. doi:10.1007/s00259-019-04511-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。